Michael Anstey
Partner at Cambridge Innovation Capital
Greater Cambridge Area
Overview
Work Experience
Partner
2017 - Current
Cambridge Innovation Capital backs world-leading life sciences and deep tech companies with a connection to Cambridge UK, Europe’s leading innovation ecosystem. As a preferred investor for the University of Cambridge, we have unparalleled access to investment opportunities in the ecosystem. Since our inception in 2013, we have raised over £500 million to invest in disruptive, deep-tech businesses in sectors including, but not limited to, artificial intelligence, internet of things, quantum technologies, autonomous systems, therapeutics, medtech/diagnostics, digital health and genomics/proteomics.
Board Member
2021
Epitopea is developing accessible "off-the-shelf" cancer immunotherapies that will deliver durable benefits. To achieve this, the company is exploiting a novel class of untapped tumour-specific antigens (TSAs), Cryptigen TSAs, designed to treat a broad patient population.
Board Member
2019
Start Codon identifies and recruits high potential life science and healthcare companies from across the UK and beyond, provides seed-funding, and leverages the world-class resources of the Cambridge ecosystem to reduce risk and prepare them for a successful Series A fundraise.
Board Member
2018
Congenica is a digital health company enabling genomic medicine with the world’s leading clinical decision support platform for the interpretation of complex genomic data.
Board Member
2018 - 2023
STORM Therapeutics is the leading company tackling disease through modulating RNA modifying enzymes and is developing a unique platform and pipeline to address these enzyme classes, including RNA methyltransferases.
Board Member
2017 - 2020
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles®, for diseases that are underserved by existing therapeutics. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA.
Co-Founder
2014 - 2018
Proteorex is a biotechnology company developing small molecule therapeutics that target protein-protein interactions implicated in disease.
Principal
2010 - 2017
The Boston Consulting Group is a global management consulting firm and the world's leading advisor on business strategy. BCG partners with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. I focused on serving multinational clients in the Health Care sector, with extensive experience working in Canada, USA, UK, India, and Japan.
BCG Securities focuses on wealth management with high net worth individuals.
Investment Analyst
2008 - 2009
Oxford Capital is a UK-based venture capital firm that specializes in investing in UK headquartered, but globally focused, science and technology businesses. I was responsible for originating, evaluating, and monitoring investments in the health care and cleantech sectors.
Education
DPhil
2003 - 2007
First Class BSc(Hons)
1999 - 2003